TickerFacts.

Monte Rosa Therapeutics, Inc. (GLUE): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$27.50M
Year ended 2025-12-31
-$32.08M
Trailing 12 months to 2026-06-30
$38.01M2020-12-31: -$26.44M2021-12-31: -$69.09M2022-12-31: -$105.38M2023-12-31: -$62.84M2024-12-31: $38.01M2025-12-31: -$27.50M-$27.50M
2020-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$27.50Mn/m2026-03-17, From 2025-01-01
2024-12-31$38.01Mn/m2026-03-17, From 2024-01-01
2023-12-31-$62.84Mn/m2025-03-20, From 2023-01-01
2022-12-31-$105.38Mn/m2024-03-14, From 2022-01-01
2021-12-31-$69.09Mn/m2023-03-16, From 2021-01-01
2020-12-31-$26.44Mn/a2022-03-29, From 2020-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Monte Rosa Therapeutics, Inc. (GLUE)2025-12-31-$27.50Mn/m
Atara Biotherapeutics, Inc. (ATRA)2025-12-31-$50.94Mn/m
Agenus Inc (AGEN)2025-12-31-$77.20Mn/m
ImmunityBio, Inc. (IBRX)2025-12-31-$308.78Mn/m
Beam Therapeutics Inc. (BEAM)2025-12-31-$360.05Mn/m
Century Therapeutics, Inc. (IPSC)2025-12-31-$104.72Mn/m
Ginkgo Bioworks Holdings, Inc. (DNA)2025-12-31-$178.72Mn/m
REGENXBIO Inc. (RGNX)2025-12-31-$126.38Mn/m
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31-$74.09Mn/m

Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗